Cargando…
Insulin-like growth factor-I inhibition with pasireotide decreases cell proliferation and increases apoptosis in pre-malignant lesions of the breast: a phase 1 proof of principle trial
INTRODUCTION: Estrogen inhibition is effective in preventing breast cancer in only up to 50% of women with precancerous lesions and many experience side effects that are poorly tolerated. As insulin-like growth factor I (IGF-I) underlies both estrogen and progesterone actions and has other direct ef...
Autores principales: | Singh, Baljit, Smith, Julia A, Axelrod, Deborah M, Ameri, Pietro, Levitt, Heather, Danoff, Ann, Lesser, Martin, de Angelis, Cristina, Illa-Bochaca, Irineu, Lubitz, Sara, Huberman, Daniel, Darvishian, Farbod, Kleinberg, David L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303192/ https://www.ncbi.nlm.nih.gov/pubmed/25385439 http://dx.doi.org/10.1186/s13058-014-0463-1 |
Ejemplares similares
-
Optimization of an automated tumor-infiltrating lymphocyte algorithm for improved prognostication in primary melanoma
por: Chou, Margaret, et al.
Publicado: (2020) -
Pasireotide in the Personalized Treatment of Acromegaly
por: Puig-Domingo, Manel, et al.
Publicado: (2021) -
Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant
por: Chiloiro, Sabrina, et al.
Publicado: (2021) -
Pasireotide for the Medical Management of Feline Hypersomatotropism
por: Scudder, C.J., et al.
Publicado: (2015) -
Systems biology perspectives on the carcinogenic potential of radiation
por: Barcellos-Hoff, Mary Helen, et al.
Publicado: (2014)